Handelsbanken Fonder’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Handelsbanken Fonder’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-69,475	Closed	-$8.04M	–	1632
2023 Q3	$8.04M	Buy	69,475 +470	+0.7%	+$50.5K	0.05%	349
2023 Q2	$7.1M	Buy	69,005 +23,570	+52%	+$2.49M	0.04%	379
2023 Q1	$4.96M	Sell	45,435 -139,685	-75%	-$15.4M	0.03%	414
2022 Q4	$21.1M	Buy	185,120 +107,443	+138%	+$8.92M	0.13%	185
2022 Q3	$4.81M	Buy	77,677 +397	+0.5%	+$27.7K	0.03%	421
2022 Q2	$6.16M	Buy	77,280 +48,180	+166%	+$4.56M	0.04%	388
2022 Q1	$3.06M	Buy	+29,100	New	+$2.84M	0.02%	524
2021 Q3	–	Sell	-37,520	Closed	-$3.51M	–	1711
2021 Q2	$3.51M	Buy	+37,520	New	+$3.45M	0.02%	534
2021 Q1	–	Sell	-40,620	Closed	-$2.97M	–	1606
2020 Q4	$2.97M	Buy	+40,620	New	+$3.02M	0.02%	526

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Handelsbanken Fonder's HZNP Position: Q4 2023 in Review

Handelsbanken Fonder sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 69,475 shares — an estimated $8.04M sold.

Handelsbanken Fonder first reported a position in HZNP in Q4 2020 and held it in 9 quarters. The position peaked at $21.1M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Handelsbanken Fonder reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Handelsbanken Fonder sold 69,475 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $8.04M.
Handelsbanken Fonder first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 9 quarters.
Handelsbanken Fonder's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $21.1M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Handelsbanken Fonder's 13F filing for Q4 2023, filed 1 Feb 2024.